Disease · MONDO_0019468
T-cell prolymphocytic leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. T-cell prolymphocytic leukemia. Diseases, record MONDO_0019468. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019468
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
CLL, T-cell, T cell CLL, T cell chronic lymphocytic leukaemia, T cell chronic lymphocytic leukemia, T cell prolymphocytic leukaemia, T prolymphocytic leukaemia, T prolymphocytic leukemia, T-PLL, chronic T-cell leukemia, chronic T-cell lymphocytic leukemia
- Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ALEMTUZUMAB | CHEMBL1201587 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VENETOCLAX | CHEMBL3137309 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALRIZOMADLIN | CHEMBL4091801 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| APG-2575 | CHEMBL4650374 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| AZACITIDINE | CHEMBL1489 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BORTEZOMIB | CHEMBL325041 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IBRUTINIB | CHEMBL1873475 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MITOXANTRONE | CHEMBL58 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets54
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| BCL2 | Apoptosis regulator Bcl-2 | 2 | Apoptosis regulator Bcl-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/596 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 2 | Tyrosine-protein kinase JAK1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| ADRM1 | 26S proteasome | 1 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| CD3E | T-cell surface glycoprotein CD3 epsilon chain | 1 | T-cell surface glycoprotein CD3 epsilon chain binding agent | Phase 2 | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD52 | CAMPATH-1 antigen | 1 | CAMPATH-1 antigen inhibitor | Phase 2 | https://conductscience.org/library/genes/1043 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 1 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| EEF2 | Elongation factor 2 | 1 | Elongation factor 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/1938 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
1 to 10 of 54
See all 54 targetsTrials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03873493 | A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia | Phase 2 | 14 | 2022-12-19 | Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer | IBRUTINIB, VENETOCLAX | Its record names the disease | ClinicalTrials.gov |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | Phase 2 | 9 | 2015-06-30 | Chronic Lymphocytic Leukemia, Leukemia | AZACITIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | Phase 1 | 113 | Solid Tumors, Chronic Lymphocytic Leukemia, T-cell-prolymphocytic Leukemia | NIRAPARIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Phase 1 | 106 | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | TINOSTAMUSTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | Phase 2 | 78 | T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | APG-2575 | Its record names the disease | ClinicalTrials.gov | |
| NCT07311746 | Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia | Phase 1/2 | 36 | T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | CLADRIBINE, RUXOLITINIB, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT00611208 | A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) | Phase 2 | 32 | T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungoides, Cutaneous T-cell Lymphoma (CTCL) | RESIMMUNE | Its record names the disease | ClinicalTrials.gov | |
| NCT01094860 | Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies | Phase 1 | 29 | Leukemia | NELARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01186640 | Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) | Phase 2 | 16 | T-cell-prolymphocytic Leukemia | ALEMTUZUMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, MITOXANTRONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03989466 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | Phase 1 | 15 | Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | ALEMTUZUMAB, ITACITINIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 12
See all 12 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019468
GET https://conductscience.org/api/diseases/v1/MONDO_0019468/targets?page=2